Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis

Author： Dunkel Petra   Chai Christina LL   Sperlágh Beáta   Huleatt Paul B   Mátyus Péter  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.9, 2012-09, pp. : 1267-1308

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Issues for Clinical Drug Development in Neurodegenerative Diseases

By Dib Michel  

Drugs, Vol. 65, Iss. 17, 2005-01 ,pp. : 2463-2479

Adis International

Access to resources Recommend Favorite

Current clinical trials in amyotrophic lateral sclerosis

By Bhatt Jaydeep M   Gordon Paul H  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 8, 2007-08 ,pp. : 1197-1207

Informa Healthcare

Access to resources Recommend Favorite

Developing a neuroprotective therapy for Parkinson’s and Huntington’s diseases

By Kazantsev Aleksey G  

Expert Opinion on Therapeutic Patents, Vol. 17, Iss. 2, 2007-02 ,pp. : 159-172

Informa Healthcare

Access to resources Recommend Favorite

Neuroprotective Effects of Fisetin in Alzheimer’s and Parkinson’s Diseases: From Chemistry to Medicine

By  

Current Topics in Medicinal Chemistry, Vol. 16, Iss. 17, 2016-07 ,pp. : 1910-1915

Bentham Science Publishers

Access to resources Recommend Favorite

Implications of Parkinson's Disease Pathophysiology for the Development of Cell Replacement Strategies and Drug Discovery in Neurodegenerative Diseases

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 7, 2012-11 ,pp. : 907-920

Bentham Science Publishers

Access to resources Recommend Favorite